Doctiplus - We are allways here!

Mn-Sn: 8am to 9pm

Diabetes (Type 2) — Weekly Report — October 5, 2026

Home/Health Insights/Diabetes (Type 2) — October 5 – October 12, 2026
Vol. 7 · No. 46
DoctiPlus Care · Weekly Brief on Diabetes (Type 2)
Updated Sunday · November 15, 2026
Diabetes (Type 2) · October 5 – October 12, 2026

Diabetes (Type 2)
Weekly Report

This week's data 33 new clinical trials registered across 10 countries, with 1,959 trials actively recruiting patients worldwide.
Week of October 5 – October 12, 2026
  • 33 new clinical trials registered across 10 countries.
  • 1,959 trials actively recruiting patients worldwide.
  • Notable trial: Prevalence and Determinants of Therapeutic Non-Compliance in Patients With Chronic Pathologies ( PDTNCCP) (3000 patients).
  • 408 new research papers published.
  • Drug safety: Most reported effect across tracked medications (metformin, semaglutide, sitagliptin, empagliflozin, insulin glargine) was Off Label Use.
  • No active drug recalls for tracked medications this week.

The week in numbers

Figures · October 5 – October 12, 2026
New Trials This Week
33.
registered Oct 5–Oct 12
Recruiting Now
1,959
active trials seeking patients
Countries
10
with active trials this week
Papers Published
408
new studies this week
Phase 3 Trials
3
late-stage trials this week
Fig. 01

Trials by country

Count · October 5 – October 12, 2026
United States
27
Not specified
11
Singapore
3
Germany
2
Italy
1
Argentina
1
Greece
1
Pakistan
1
Iran
1
Canada
1
0 7 14 21 27
total
Fig. 02

Trials by phase

Distribution · October 5 – October 12, 2026

New clinical trials registered this week for Diabetes (Type 2). Each trial links to its full record on ClinicalTrials.gov where you can find eligibility criteria, locations, and contact information.

§ 03

This week's new registrations

Click any header to sort

33 trials registered for Diabetes (Type 2). Each links to its full record on ClinicalTrials.gov.

# Trial ↓ Phase ↕ Status ↕ Enrollment ↕ Country ↕
01 Glycemic Impact of NNS Via the Gut Microbiome Diabetes (Type 2) · Tufts University (NCT07868432) Other Enrolling By Invitation 10 United States
02 Strategy For Assessing The Risk Of Type 1 Diabetes In Pediatric Celiac Patients Diabetes (Type 2) · University of Bari (NCT07862101) Other Recruiting 600 Italy
03 Oral VK2735 for Weight Management in Adults With Type 2 Diabetes Mellitus Phase 3 (SUNRISE 2) Diabetes (Type 2) · Viking Therapeutics, Inc. (NCT07868939) Phase 3 Not Yet Recruiting 560 N/A
04 Inspiratory Muscle Strength Training in Adults With Type 1 Diabetes Diabetes (Type 2) · Florida State University (NCT07859943) Other Not Yet Recruiting 30 United States
05 Evaluation of MiniMed Next Generation Extended Wear Sensors and Algorithm in Patients With Type 1 and Type 2 Diabetes Diabetes (Type 2) · Medtronic MiniMed, Inc. (NCT07864168) Other Recruiting 1,500 United States
06 LIfestyle MEtabotype Study A Diabetes (Type 2) · German Institute of Human Nutrition (NCT07868601) Other Recruiting 300 Germany
07 Continuous Delivery of Ranibizumab Via the Port Delivery System for Proliferative Diabetic Retinopathy-related Vitreous Hemorrhage With Pars Plana Vitrectomy and Limited PRP. Diabetes (Type 2) · Southeast Retina Center, Georgia (NCT07864480) Phase 4 Not Yet Recruiting 20 United States
08 A Research Study Investigating How Adults With Overweight or Obesity, With or Without Type 2 Diabetes, Tolerate Switching to a New Treatment (Zenagamtide) From Their Current Tirzepatide Medication Diabetes (Type 2) · Novo Nordisk A/S (NCT07868354) Phase 1 Not Yet Recruiting 60 United States
09 Insul-In This Together: Leveraging Family Support and Diabetes Technology for Adolescents Living With Type 1 Diabetes Diabetes (Type 2) · Stanford University (NCT07856836) Other Not Yet Recruiting 200 United States
10 Clinical Trial for the Study of Stress and Exercise Impact on Glucose Levels and Additional Physiological Signals. Stress, Insulin and Exercise Study: a Trial in Argentina Diabetes (Type 2) · National Council of Scientific and Technical Research, Argentina (NCT07865923) Other Completed 5 Argentina
11 A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of SYS6088 in Patients With Advanced/Metastatic Solid Tumors Diabetes (Type 2) · CSPC Megalith Biopharmaceutical Co.,Ltd. (NCT07857135) Phase 2 Not Yet Recruiting 140 N/A
12 DiaBuddy: AI-Enabled Digital Self-Management for Youth With Type 1 Diabetes Diabetes (Type 2) · Dr. Juwayria Omar (NCT07861373) Other Not Yet Recruiting 140 N/A
13 Food Prescription Among Youth With Type 1 Diabetes Diabetes (Type 2) · Baylor College of Medicine (NCT07860229) Other Not Yet Recruiting 45 N/A
14 Oral VK2735 for Weight Management Phase 3 (SUNRISE 1) Diabetes (Type 2) · Viking Therapeutics, Inc. (NCT07868835) Phase 3 Not Yet Recruiting 560 N/A
15 Measuring Plantar Pressures in Diabetic Patients With Lateral Forefoot Amputation Diabetes (Type 2) · Nanyang Technological University (NCT07865208) Other Recruiting 70 Singapore
16 Diabetes Distress, Medication Adherence Barriers, Self-Management, and Glycemic Control in Adults With Type 2 Diabetes Diabetes (Type 2) · Bilecik Seyh Edebali Universitesi (NCT07861308) Other Not Yet Recruiting 137 N/A
17 A Trial to Evaluate the Efficacy and Safety of ARO-INHBE in Adults With Metabolic Dysfunction-Associated Steatohepatitis Diabetes (Type 2) · Arrowhead Pharmaceuticals (NCT07859813) Phase 2 Not Yet Recruiting 252 N/A
18 Randomized, Controlled Study to Investigate the 12-month Efficacy and Safety of Resveratrol Vitamin Supplements in Patients With Non-proliferative Diabetic Retinopathy Without Center Involved Diabetic Macular Edema (REVOLUTION Study) Diabetes (Type 2) · University of Athens (NCT07868458) Phase 4 Completed 100 Greece
19 Comparing The Effect Of Empagliflozin With Dapagliflozin In Reducing Proteinuria In Diabetic Patients With Chronic Kidney Disease With eGFR More Than 45ml/Min/1.73m² Diabetes (Type 2) · Lahore General Hospital (NCT07866235) Other Completed 116 Pakistan
20 Effects of High-Intensity Interval Training and Quinoa Supplementation in Women With Type 2 Diabetes Diabetes (Type 2) · University of Central Lancashire (NCT07863934) Other Completed 32 Iran
21 Awareness of Bidirectional Relation of Diabetes Mellitus and Periodontal Health Diabetes (Type 2) · Cairo University (NCT07858604) Other Not Yet Recruiting 323 N/A
22 Advancing Health Equity and Preventive Cardiovascular Care in Indigenous and Remote Communities: a Mobile Healthcare Unit Diabetes (Type 2) · Laval University (NCT07869069) Other Recruiting 500 Canada
23 Prevalence and Determinants of Therapeutic Non-Compliance in Patients With Chronic Pathologies ( PDTNCCP) Diabetes (Type 2) · University of Monastir (NCT07864532) Other Completed 3,000 Tunisia
24 Role of Renal Duplex Resistive Index (RRI) and Pulsatility Index (PI) in Assessment of Early Renal Microvascular Changes in Diabetic Patient Diabetes (Type 2) · Assiut University (NCT07864740) Other Not Yet Recruiting 84 N/A
25 Tracking Income Dynamics and Everyday Health Study Diabetes (Type 2) · University of Pennsylvania (NCT07862452) Other Not Yet Recruiting 400 United States
26 GLP-1 Receptor Agonist Use and Sarcopenia in Obese Individuals Without Diabetes Diabetes (Type 2) · Istanbul Saglik Bilimleri University (NCT07858864) Other Recruiting 42 Turkey (Türkiye)
27 Electromagnetic Therapy, Peripheral Vascular Diseases, Diabetes Diabetes (Type 2) · Ashraf Abdelaal (NCT07864805) Other Completed 60 Saudi Arabia
28 RESET-INSPIRE Study: Insulin Sensitivity & Population Intervention With Real-time Evaluation Using CGM Diabetes (Type 2) · National University Health System, Singapore (NCT07861191) Other Recruiting 270 Singapore
29 Clinical Decision Support for SGLT2i After AKI in Type 2 Diabetes Diabetes (Type 2) · University of Minnesota (NCT07868666) Other Not Yet Recruiting 250 N/A
30 Managing Pasireotide-associated Hyperglycaemia in Acromegaly With Ketogenic Diet Diabetes (Type 2) · Leiden University Medical Center (NCT07866846) Other Recruiting 30 Netherlands
31 System Accuracy of the Blood Glucose Monitor for Personal Use Aria Diabetes (Type 2) · Institut fur Diabetes Karlsburg GmbH (NCT07859501) Other Completed 105 Germany
32 Maridebart Cafraglutide Versus Semaglutide in Participants With Type 2 Diabetes Diabetes (Type 2) · Amgen (NCT07866066) Phase 3 Not Yet Recruiting 1,300 N/A
33 KPSC MNT Pilot RCT Diabetes (Type 2) · Kaiser Permanente (NCT07868250) Other Recruiting 600 United States
§ 04

Adverse event reports

FDA FAERS · 2025 data

Adverse drug event reports compiled from the FDA's FAERS database for medications commonly prescribed for Diabetes (Type 2). These reports reflect what patients and healthcare providers have reported — they do not confirm a drug caused the effect.

Reports by drug

DrugTop effectCount
metformin Diarrhoea 2,240
semaglutide Nausea 2,963
sitagliptin Nausea 330
empagliflozin Nausea 823
insulin glargine Off Label Use 4,775

Recalls & safety notices

§ 05 · 0 items this week

FDA drug recall notices for medications related to Diabetes (Type 2). If your medication is listed, contact your pharmacist or visit fda.gov/safety/recalls for guidance. No recall listed does not guarantee safety — always consult your healthcare provider.

No active drug recalls for tracked medications this period.

§ 06

Published research

408 papers

Recently published peer-reviewed studies related to Diabetes (Type 2), sourced from PubMed and Semantic Scholar. Click any title to read the full paper, or expand the abstract for a quick summary.

# Study Journal Date Source
01 Pregnancy Complicated by Citrin Deficiency and Gestational Diabetes Mellitus: Perioperative Metabolic Management and Postoperative Analgesic Challenges Following Caesarean Delivery. Naing EEP et al. 10.7759/cureus.117730
View abstract

Citrin deficiency is a rare autosomal recessive metabolic disorder caused by pathogenic variants in the SLC25A13 gene. Pregnancy in affected women is uncommon and presents unique challenges because conventional obstetric management may conflict with metabolic requirements. The coexistence of gestational diabetes mellitus (GDM) introduces additional complexity. A 25-year-old, gravida 2 para 0+1 woman with genetically confirmed citrin deficiency (homozygous c.1763G>A mutation) was managed jointly by obstetric and inherited metabolic disease (IMD) teams. Her pregnancy was complicated by severe nausea and vomiting during the first trimester and subsequent GDM diagnosed using capillary glucose monitoring rather than an oral glucose tolerance test. Representative fasting glucose values were 6.3-6.8 mmol/L, with postprandial values up to 10.7 mmol/L. Specialist dietary modification and insulin therapy were instituted following multidisciplinary review. A personalised metabolic plan emphasised avoidance of prolonged fasting, restriction of excessive carbohydrate intake, maintenance of adequate energy intake, and avoidance of routine glucose-containing intravenous fluids. At 38+5 weeks' gestation, she underwent emergency caesarean section for failure to progress in labour under spinal anaesthesia. A healthy infant weighing 3074 g was delivered with Apgar scores of 9, 10 and 10 at 1, 5 and 10 minutes, respectively. Postoperative pain management was challenging because the specialist metabolic plan advised caution with paracetamol. Following inadequate analgesia with ibuprofen and dihydrocodeine, paracetamol was cautiously introduced at reduced doses and subsequently increased to 500 mg four times daily, with additional opioid analgesia as required. Daily plasma ammonia and liver function monitoring was undertaken during the five-day postoperative admission; ammonia values remained within the laboratory reference range, with no hyperammonaemia (range <10-32 µmol/L) or significant hepatic biochemical deterioration. This case highlights the complexity of managing pregnancy in women with citrin deficiency, particularly when complicated by GDM. It also demonstrates a practical approach to postoperative analgesia following caesarean delivery using cautious dose escalation and biochemical surveillance.

Cureus 2026 Oct PubMed
02 Lithocholic Acid Improves Glucose Homeostasis by Activating the TGR5-GLP-1 Axis via Gut Microbiota-Derived Secondary Bile Acids: A Study Done on Diabetic Sprague-Dawley Rats. Xu C et al. 10.2147/DMSO.S627840
View abstract

PURPOSE: This study aimed to investigate the effects of lithocholic acid on glucose metabolism in streptozotocin -induced diabetic Sprague-Dawley (STZ-DM) rats and to explore its potential mechanisms. METHODS: STZ-DM rats were randomly allocated into two groups (n=6 per group) and received LCA (50 mg/kg/d) or vehicle by daily gavage for 6 weeks. Longitudinal monitoring of body weight and fasting blood glucose was performed throughout the intervention, and oral glucose tolerance tests were conducted to evaluate glucose metabolic capacity. Fecal bile acid metabolomics and gut microbial community analyses were further conducted. Additionally, the transcriptional levels of ileal TGR5, FXR and GLP-1, as well as the key hepatic gluconeogenic genes G6PC and PCK1, were quantified by RT-qPCR at the mRNA level for mechanistic exploration. RESULTS: LCA treatment reduced fasting glycemia and enhanced glucose tolerance, accompanied by a significant suppression of hepatic G6PC and PCK1 mRNA, with no significant impact on body weight. A marked elevation in fecal secondary bile acids was observed, showing a positive correlation with metabolic improvements. LCA supplementation enriched intestinal Clostridia, which correlated with secondary bile acid abundance and glucose homeostasis indicators. Meanwhile, ileal and hepatic TGR5 as well as ileal GLP-1 mRNA expression were upregulated following LCA administration. CONCLUSION: LCA is associated with improved glucose metabolism in STZ-DM rats, potentially through TGR5-GLP-1 activation and suppression of hepatic gluconeogenesis, in conjunction with Clostridium-enriched secondary bile acid production. However, this study only relies on mRNA expression data and lacks functional TGR5 receptor validation; the proposed correlative pathway requires further mechanistic verification to confirm causal effects.

Diabetes, metabolic syndrome and obesity : targets and therapy 2026 PubMed
03 The Role of TXNIP in Skeletal Muscle Physiology and Related Diseases: Current Perspectives. Du J et al. 10.2147/JIR.S637774
View abstract

Thioredoxin-interacting protein (TXNIP) is a multifunctional regulatory protein of the α-arrestin family that acts as a redox sensor, an energy-responsive molecule, and a transcription-associated regulator. TXNIP has emerged as a key regulator of skeletal muscle homeostasis and has been implicated in the pathogenesis of multiple muscle disorders. Skeletal muscle is a principal site of systemic glucose disposal, accounting for more than 70% of insulin-stimulated glucose uptake in the human body. TXNIP has been implicated in sarcopenia, obesity-related insulin resistance, limb ischemia-induced muscle injury, disuse muscle atrophy, and hereditary muscular dystrophy through multiple mechanisms, including glutathione metabolic regulation, ferroptosis, NLRP3 inflammasome activation, impaired GLUT4 membrane translocation, and altered mitochondrial substrate oxidation. Recent advances in gene editing, single-cell sequencing, metabolomics, and human clinical research have enabled a more detailed characterization of TXNIP-related molecular mechanisms in skeletal muscle. This review provides a systematic synthesis of recent evidence on TXNIP in skeletal muscle, organized around seven themes: its molecular characteristics, expression and regulatory patterns in skeletal muscle, physiological functions, disease-specific pathogenic mechanisms, intervention-related regulatory networks, current limitations, and future perspectives. This review aims to provide a mechanistic rationale for targeting TXNIP as a potential strategy for the prevention and treatment of skeletal muscle-related diseases.

Journal of inflammation research 2026 PubMed
04 HMGCS2 Palmitoylation Promotes Diabetes-Induced Erectile Dysfunction Through PPARα-Mediated Macrophage Extracellular Trap Formation. Zhang C et al. 10.2147/JIR.S623377
View abstract

INTRODUCTION: Diabetes mellitus-induced erectile dysfunction (DMED) is a prevalent complication with limited therapeutic options for non-responders to conventional treatments. Macrophage extracellular traps (METs) are implicated in various pathologies, but their role and regulatory mechanisms in DMED remain unclear. This study investigates the role of HMGCS2 palmitoylation in promoting MET formation and DMED pathogenesis through PPARα interaction. METHODS: In vitro models were established using RAW264.7 macrophages treated with high glucose (HG) and palmitic acid (PA). A DMED rat model was induced by high-fat diet and streptozotocin injection, followed by administration of the palmitoylation inhibitor CMA (cyano-myracrylamide). HMGCS2 palmitoylation, protein expression, and its interaction with PPARα were assessed using acyl-biotin exchange (ABE) and co-immunoprecipitation (Co-IP) assays. MET formation, reactive oxygen species (ROS) production, oxidative stress markers (MDA, GSH), mitochondrial function (MMP, ATP, morphology), macrophage infiltration, and cell apoptosis were evaluated via Western blot, immunofluorescence, ELISA, transmission electron microscopy, flow cytometry, and TUNEL staining. Erectile function was assessed in vivo by apomorphine-induced penile erection tests. RESULTS: HMGCS2 expression and palmitoylation were significantly upregulated in both HG/PA-treated macrophages and corpus cavernosum of DMED rats. CMA treatment effectively reduced HMGCS2 palmitoylation, attenuated its interaction with PPARα, and downregulated HMGCS2 expression. Consequently, pharmacological inhibition of palmitoylation suppressed HG/PA-induced MET formation, ROS overproduction, oxidative stress, and mitochondrial dysfunction in vitro. In DMED rats, CMA administration significantly improved penile erectile function, which recovered to 78% of the number of erections of the control group per unit time, as well as reduced peripheral blood PA levels, and alleviated pathological changes in corpus cavernosum. Furthermore, CMA inhibited MET formation, reduced macrophage infiltration, suppressed ROS and oxidative stress, and decreased cell apoptosis in vivo. CONCLUSION: Our findings demonstrate that HMGCS2 palmitoylation drives DMED pathogenesis by promoting MET formation through enhanced PPARα interaction. Targeting HMGCS2 palmitoylation represents a promising therapeutic strategy for DMED.

Journal of inflammation research 2026 PubMed
05 Physical Activity, Myokine-Adipokine Signatures and Haemoglobin Glycation Index in Adults with Type 2 Diabetes. Ismail M et al. 10.2147/DMSO.S621983
View abstract

BACKGROUND: The Hemoglobin Glycation Index (HGI) reflects variability in hemoglobin glycation beyond ambient glycaemia and is a marker of metabolic heterogeneity, cardiovascular risk and treatment response in type 2 diabetes mellitus (T2DM). Whether circulating myokines and adipokines are related to HGI, or whether relationships differ across exercise modalities, is unclear. OBJECTIVE: To examine associations of circulating myokines (irisin, myostatin, myonectin, IL-6, IL-15) and adipokines (leptin, adiponectin) with HGI, and whether associations differ between physically active and sedentary individuals and across exercise modalities. METHODS: Cross-sectional study of 185 adults with T2DM recruited at Thumbay Hospital, Ajman, United Arab Emirates, classified as physically active (n=98) or sedentary (n=87), with active individuals sub-grouped by predominant modality: aerobic (70), resistance (11), combined (17). Measurements were obtained after an overnight fast. HGI was calculated as the residual of HbA1c regressed on fasting plasma glucose. Mann-Whitney U, Kruskal-Wallis, Spearman correlations with false discovery rate (FDR) correction and median regression adjusted for age, sex, BMI and fasting glucose were used. RESULTS: Active participants had lower HGI than sedentary participants (median -0.44 vs 0.12; p = 0.001), with lower BMI, fasting glucose and HbA1c. HGI differed by modality (p < 0.001), most favourable in the combined-training group and least favourable in the aerobic-only group. IL-6 was inversely correlated with HGI in active participants and leptin in sedentary participants (both FDR p < 0.05). Physical activity remained an independent predictor of lower HGI after adjustment for age, sex and BMI (β = -0.65;p< 0.001), and persisted after adjustment for IL-15 and leptin. CONCLUSION: Precludes causal inference; if confirmed prospectively, associations may inform individualized exercise prescription and HGI-based risk stratification.Distinct myokine-adipokine signatures were associated with glycation variability beyond mean glycaemia and combined aerobic-plus-resistance training with the most favourable HGI profile. The cross-sectional design precludes causal inference; if confirmed prospectively, associations may inform individualized exercise prescription and HGI-based risk stratification.

Diabetes, metabolic syndrome and obesity : targets and therapy 2026 PubMed
06 Severe Euglycemic Diabetic Ketoacidosis After Semaglutide-Associated Poor Intake Despite Empagliflozin Discontinuation: A Case Report. Niknam K et al. 10.2147/IMCRJ.S650090
View abstract

Euglycemic diabetic ketoacidosis (EDKA) may be overlooked when serum glucose is near normal. A 68-year-old woman with long-standing type 2 diabetes developed approximately three weeks of nausea, intermittent vomiting and diarrhea, and minimal oral intake after semaglutide initiation at 0.25 mg once weekly for four weeks followed by 0.5 mg once weekly. Patient and family medication reconciliation indicated that she had stopped empagliflozin, metformin, and pioglitazone approximately two weeks before presentation but continued semaglutide, with the last dose approximately eight days before admission. She presented with weakness, dyspnea, slowed speech, and disorientation. Initial testing showed glucose 132 mg/dL, venous pH 7.13, bicarbonate 9 mmol/L, anion gap 26 mmol/L, and beta-hydroxybutyrate 99.5 mg/dL. She improved with intravenous crystalloid, dextrose-containing fluids, insulin infusion, and electrolyte replacement. The temporal association is consistent with a clinically plausible contribution from semaglutide-associated gastrointestinal intolerance and carbohydrate depletion to EDKA despite reported prior empagliflozin discontinuation. Normal glucose should not delay ketone and acid-base testing when compatible symptoms and poor intake are present.

International medical case reports journal 2026 PubMed
07 Red Cell and Platelet Indices as Biomarkers of Poor Glycemic Control in Patients With Type 2 Diabetes: A Case-Control Study. Owusu-Asante H et al. 10.1002/hsr2.73382
View abstract

BACKGROUND AND AIM: Type 2 diabetes mellitus (T2DM) is associated with systemic inflammation and altered hematological function, including changes in red cell indices and platelet hyperreactivity. While glycosylated hemoglobin (HbA1c) is the gold standard for monitoring glycemic control, its cost and susceptibility to conditions like anemia highlight the need for accessible, reliable alternative biomarkers, particularly for identifying patients with poor glycemic control (HbA1c ≥ 7.0%). This case-control study, therefore, investigated the utility of red cell and platelet indices as potential biomarkers of poor glycemic control in Ghanaian T2DM patients. METHODS: This study recruited 134 people living with T2DM and 134 nondiabetic controls. Cases were categorized into groups with poor glycemic control (HbA1c ≥ 7.0%) and good glycemic control (HbA1c < 7.0%). HbA1c was measured using an automated analyzer, and hematological indices were measured using a Sysmex XN 2000 analyzer. Statistical analyses were performed in R Language and SPSS version 26 at a significance level of 0.05% and 95% confidence interval employing a logistic prediction model. RESULTS: Prevalence of poor glycemic control was 60.9%. Cases with poor glycemic control had significantly lower red cell indices such as hemoglobin, hematocrit, red blood cells count, and MCV, but a higher MPV compared to controls ( < 0.05). Multivariate logistics regression showed increasing hemoglobin levels (aOR: 0.40, 95% CI: [0.11-0.78];  = 0.0130) and hematocrit (aOR: 0.03, 95% CI: [0.01-0.92];  = 0.0140) were independently associated with decreased likelihood of poor glycemic control, whiles increasing MPV (aOR: 1.15, 95% CI: [1.02-3.09];  = 0.0440) demonstrated an independent association with increased likelihood of poor glycemic control. CONCLUSION: Hemoglobin level, hematocrit, and mean platelet volume are significantly associated with, and can potentially serve as independent predictors of poor glycemic control. These routine, cost-effective hematological parameters could be incorporated into risk assessment and management protocols for T2DM in resource-limited settings.

Health science reports 2026 Oct PubMed
08 Temporal Association Between Aromatase Inhibitor Initiation and New-Onset Atrial Fibrillation: A Case Report. Prevete S et al. 10.1177/87551225261492174
View abstract

INTRODUCTION: Breast cancer is the most prevalent cancer among women worldwide with a higher probability of diagnosis in the postmenopausal years. Aromatase inhibitors (AIs) block the aromatase enzyme responsible for converting androgens into estrogens in the peripheral tissues, which become the main source for estrogen production in this population. Estrogen plays a key role in promoting vasodilation and inhibiting vascular injury and atherosclerosis development. Reduced levels can contribute to adipocyte hyperplasia, insulin resistance, and dyslipidemia, all of which are risk factors for atrial fibrillation. PATIENT CASE: We describe the case of a 71-year-old postmenopausal female who presented to the emergency department with shortness of breath and was subsequently diagnosed with new-onset atrial fibrillation. This case report aims to evaluate whether there is a potential correlation between the initiation of an AI and the development of atrial arrhythmias. DISCUSSION: While existing data suggest an association between AI use and atrial fibrillation, there lacks an elaborate understanding of the temporal relationship between the 2. This case highlights a potential association between AI therapy and unusually rapid-onset atrial fibrillation, demonstrating the need for further research and increased clinical awareness when managing patients receiving these treatments.

The Journal of pharmacy technology : jPT : official publication of the Association of Pharmacy Technicians 2026 Oct 8 PubMed
09 Bone marrow adipose tissue in cardiometabolic disease: marrow niche remodeling, inflammatory hematopoiesis, and vascular pathology. Ma Z et al. 10.1007/s12020-026-04824-z
View abstract

Bone marrow adipose tissue (BMAT) is increasingly recognized as a metabolically active, endocrine, and immunomodulatory component of the marrow niche rather than a passive fat depot. This narrative review synthesizes biological, imaging, epidemiological, and therapeutic evidence linking BMAT and marrow metabolic activation with cardiometabolic disease. BMAT arises from marrow stromal progenitors and exhibits depot-specific heterogeneity, endocrine activity, insulin responsiveness, and context-dependent expansion during aging, diabetes, obesity, menopause, osteoporosis, and chronic kidney disease. Mechanistically, experimental studies indicate that marrow adipocytes and adipocyte-lineage niche cells can influence hematopoiesis through metabolic and local signaling, whereas trained immunity is established primarily in HSPCs, myeloid progenitors, and monocyte/macrophage populations. Human MRI/MRS studies characterize BMAT quantity and composition, whereas F-FDG PET reflects non-BMAT-specific marrow activation associated with vascular inflammation and early atherosclerosis; direct BMAT-cardiovascular evidence remains limited. Emerging population imaging and genetic analyses support BMAT as a disease-associated phenotype, particularly for osteoporosis and fractures. Interventions affecting metabolic, inflammatory, skeletal, or marrow pathways have differing degrees of BMAT-related evidence, and none has established that modifying BMAT improves cardiovascular outcomes. This review identifies BMAT as an emerging research phenotype while emphasizing that its causal, prognostic, and therapeutic relevance to cardiovascular disease remains unresolved.

Endocrine 2026 Oct 10 PubMed
10 Post-dexamethasone cortisol levels in non-functioning adrenal incidentalomas: a pooled individual participant data analysis. Chiodini I et al. 10.1007/s12020-026-04832-z
View abstract

INTRODUCTION: Non-functioning adrenal incidentalomas (NFAI) are defined by 1 mg-dexamethasone suppression test (F-1mgDST) cortisol levels < 1.8 µg/dL. However, many individuals with NFAI may exhibit subtle hypercortisolism associated with increased cardiometabolic and skeletal risk. The aims of the present study are to compare F-1mgDST distributions between individuals with NFAI and population-based controls and to explore whether alternative F-1mgDST thresholds would meaningfully modify patient classification. METHODS: This is a pooled individual participant data analysis of 7 studies evaluating cortisol secretion in patients with type 2 diabetes, osteoporosis and/or fragility fractures, hypertension, or adrenal incidentalomas. The study included 1681 participants (915 NFAI, 766 controls) with F-1mgDST < 1.8 µg/dL. Data included age, sex, body mass index (BMI), F-1mgDST, and adrenocorticotroph hormone (ACTH). We assessed the between-group differences in F-1mgDST and ACTH and the accuracy of different F-1mgDST thresholds for identifying NFAI. RESULTS: Compared to controls, patients with NFAI had lower age and ACTH levels (62.1 ± 9.8 and 59.8 ± 12.0 years, 25.1 ± 14.1 pg/mL and 16.3 ± 10.4, respectively, p < 0.001 for all comparisons), but higher BMI and F-1mgDST values (28.1 ± 4.9 and 29.0 ± 5.0 kg/m, 1.04 ± 0.37 µg/dL and 1.13 ± 0.39 µg/dL, respectively, p < 0.001 for all comparisons) and were more less frequently females (48.0% and 38.6%, respectively, p < 0.001). A propensity score analysis performed on 730 patients and 730 age-, BMI- and gender-matched controls confirmed these findings. We did not identify any F-1mgDST threshold with an accuracy exceeding 60% for distinguishing controls from patients with NFAI. The F-1mgDST threshold the best balance between sensitivity (54.8%) and specificity (57.2%) was set at 1.1 µg/dL (30 nmol/L), although with a low accuracy of 55.8%. CONCLUSIONS: Individuals with NFAI have higher F-1mgDST levels than controls. More than 40% overlap exists in F-1mgDST values between NFAI and controls.

Endocrine 2026 Oct 10 PubMed
11 Severity-associated endothelial dysfunction in post-COVID-19 patients: flow-mediated dilation and vasoactive biomarkers. Palii SM et al. 10.1007/s11239-026-03404-2
View abstract

COVID-19 is frequently associated with endothelial dysfunction, characterized by an imbalance between vasodilatory and vasoconstrictive mediators. This study evaluated endothelial function in the early post-COVID-19 period across groups of acute disease severity using flow-mediated dilation (FMD), circulating vasoactive biomarkers, and echocardiography. Serum endothelin-1 (ET-1), arginase-1 (Arg1), thromboxane A₂ (TxA₂)-related immunoreactivity, and prostacyclin (PGI₂)-related immunoreactivity were measured by enzyme-linked immunosorbent assay. An impaired FMD response was defined as < 10% brachial artery dilation from baseline. Overall, 502 post-COVID-19 patients were classified by acute COVID-19 severity as mild (n = 262), moderate (n = 183), severe (n = 41), or critical (n = 16); 27 healthy individuals served as a reference group. Impaired FMD responses were more frequent after severe (90.24%) and critical (100.00%) disease than in the reference group (18.52%). Greater acute disease severity was associated with progressively lower FMD values, smaller absolute brachial artery diameter changes, higher ET-1, Arg1, and TxA₂-related immunoreactivity, and lower PGI₂-related immunoreactivity. After adjustment for age, sex, body mass index, systolic blood pressure, smoking, diabetes mellitus, pre-existing cardiovascular disease, and post-COVID-19 interval, acute disease severity remained associated with impaired FMD (adjusted odds ratio 3.32, 95% confidence interval 2.29-4.82; p < 0.001 per one-category increase). Biomarker-FMD correlations were generally weak. Among patients assessed during the early post-COVID-19 period, greater acute COVID-19 severity was associated with greater impairment of endothelium-dependent vasodilation and an altered profile of circulating vasoactive biomarkers. These findings indicate associated functional and biochemical vascular abnormalities without establishing causality or a mechanistic relationship. Prospective longitudinal studies are needed to clarify their temporal evolution and clinical significance.

Journal of thrombosis and thrombolysis 2026 Oct 10 PubMed
12 Body Mass Index Variability and Cardiovascular Risk: Contemporary Evidence and Clinical Implications for Diabetes Care. Kaze AD et al. 10.1007/s11892-026-01648-z
View abstract

PURPOSE OF REVIEW: To synthesize contemporary evidence on body mass index (BMI) variability as a determinant of cardiovascular risk, integrate mechanistic insights, and clarify its clinical relevance in individuals with and without diabetes. RECENT FINDINGS: Large cohort studies demonstrate that greater BMI or weight variability is associated with increased risks of all-cause mortality, atherosclerotic cardiovascular disease, heart failure and atrial fibrillation, independent of mean BMI. Mechanistic evidence to explain the observed association implicates adipose tissue dysfunction, ectopic fat deposition, metabolic instability, systemic inflammation, and autonomic imbalance. Diabetes may amplify these pathways through impaired metabolic flexibility and treatment-related weight fluctuations. Evidence from diabetes-specific cohorts suggests that structured, intentional weight loss may attenuate the adverse associations seen with unstructured weight cycling. BMI variability is an emerging marker of cardiometabolic instability with implications for cardiovascular risk, particularly in diabetes. Defining actionable thresholds and determining whether stabilizing weight improves outcomes are key future research priorities.

Current diabetes reports 2026 Oct 10 PubMed
13 Dynamic transitions from prediabetes to diabetes and incident cardiovascular events in middle-aged and older chinese adults: a nationwide longitudinal study. Liang S et al. 10.1007/s12020-026-04799-x
View abstract

BACKGROUND: Prediabetes is a heterogeneous metabolic state that may revert to normoglycemia, persist, or progress to type 2 diabetes mellitus (T2DM). However, the cardiovascular implications of different prediabetes transition patterns and the ability to predict diabetes progression among middle-aged and older Chinese adults remain unclear. We aimed to characterize glycemic transitions, examine their associations with incident cardiovascular events, and develop prediction models for progression from prediabetes to T2DM. METHODS: This longitudinal cohort study used data from the China Health and Retirement Longitudinal Study. Glycemic status was defined according to American Diabetes Association criteria using fasting plasma glucose, HbA1c, self-reported diabetes, and medication use. Four-year glycemic transitions from Wave 1 to Wave 3 were assessed among 7,927 participants. Among participants with baseline prediabetes, multinomial logistic regression was used to identify factors associated with reversion to normal glucose tolerance or progression to T2DM. A Wave 3 landmark design was applied to examine subsequent incident heart disease and stroke in separate outcome-specific cohorts. Prediction models for 4-year T2DM progression were developed and internally validated using a stratified 70:30 training-test split; no external validation was performed. RESULTS: Among 3,313 participants with baseline prediabetes, 696 (21.01%) reverted to normal glucose tolerance, 2,007 (60.58%) remained in prediabetes, and 610 (18.41%) progressed to T2DM over 4 years. Higher BMI, fasting glucose, HbA1c, dyslipidemia, smoking, and C-reactive protein, together with lower grip strength, were associated with higher odds of progression. Older age, male sex, higher fasting glucose, and higher HbA1c were associated with lower odds of reversion. Compared with stable normal glucose tolerance, prediabetes progression was associated with higher odds of incident heart disease (adjusted odds ratio [aOR], 1.53; 95% CI, 1.13-2.09), whereas the association with incident stroke was not statistically significant (aOR, 1.29; 95% CI, 0.90-1.87). Stable T2DM was associated with higher odds of both incident heart disease (aOR, 1.36; 95% CI, 1.04-1.79) and stroke (aOR, 1.44; 95% CI, 1.05-1.97). The full-variable logistic regression model achieved the highest discrimination for T2DM progression (AUC, 0.715; 95% CI, 0.674-0.754), modestly outperforming the clinical baseline model (AUC, 0.699; 95% CI, 0.656-0.739) and the evaluated tree-based models. CONCLUSIONS: Prediabetes showed dynamic 4-year transitions within the analytic cohort. Progression from prediabetes to T2DM was associated with higher subsequent odds of incident heart disease, whereas its adjusted association with incident stroke was not statistically significant. The full-variable logistic regression model showed moderate discrimination and only limited incremental improvement over the clinical baseline model; it should therefore be considered an exploratory risk-stratification tool requiring external validation rather than a clinically deployable prediction model.

Endocrine 2026 Oct 10 PubMed
14 Terpenes and terpenoids modulating TRPV channels in diabetes: role in fibrosis and inflammatory signaling. Awate SA et al. 10.1007/s11033-026-12875-8
View abstract

Transient receptor potential vanilloid (TRPV) channels are non-selective cation channels that mediate thermosensation, nociception, osmotic balance, and metabolic regulation. In diabetes, altered TRPV channel expression and decreased calcium influx key pathways modulates, include NF-κB, AMPK, and TGF-β, promoting extracellular matrix accumulation and fibrotic remodelling. The limited availability of pathway specific interventions highlights TRPV channels as potential therapeutic target in diabetes. Recently, natural phytoconstituents have shown to exhibit TRPV channel modulating properties. Studies also highlights the potential of terpenes and terpenoids to inhibit NF-κB mediated inflammation, and activate AMPK-promoted metabolic homeostasis, mitigating diabetes-associated tissue damage. Preclinical studies have explored major terpenoids such as d-limonene, p-cymene and carvacrol in diabetic models. These compounds have been reported to improve glucose tolerance and alter the blood glucose levels via different molecular mechanisms. Clinically, there are limited evidences reporting terpenoids in the metabolic syndrome and TRPV modulation. Example, Astaxanthin, a tetraterpenoid has multiple human trials in type 2 diabetes, reducing diabetic biomarkers like SIRT1, HbA1c, and fasting glucose. This review summarizes current evidence on terpenes and terpenoids in diabetes with their reported and proposed interactions with TRPV1, TRPV4 with particular emphasis on their potential links to oxidative stress, NF-κB-mediated inflammation, TGF-β-associated fibrosis, and metabolic signaling. By distinguishing experimentally supported TRPV modulation with mechanistic associations and which require further validation, this review provides an integrated framework for understanding potential contribution of terpenoid-TRPV interactions to diabetes progression and its inflammatory and fibrotic complications, while highlighting key gaps for future experimental and translational investigation.

Molecular biology reports 2026 Oct 10 PubMed
15 Metabolic stress remodels the Golgi-sphingolipid-lipid droplet axis in INS-1E β-cells: an integrated molecular signature of early β-cell vulnerability. Başçıl Tütüncü N et al. 10.1007/s11033-026-12857-w
View abstract

BACKGROUND: Glucotoxicity, lipotoxicity, and glucolipotoxicity contribute to pancreatic β-cell dysfunction in type 2 diabetes. Although endoplasmic reticulum stress has been widely studied, the response of the Golgi apparatus to metabolic stress and its relationship with sphingolipid metabolism, lipid droplets, and insulin granule-associated pathways remain poorly understood. We examined these processes together in INS-1E β-cells exposed to different forms of metabolic stress. METHODS AND RESULTS: INS-1E cells were exposed to high glucose (33 mM), palmitic acid (0.5 mM), or both for 24 h. Cellular metabolic activity was measured by MTT assay. The expression of CREB3, ARF4, SMPD1, SMPD2, perilipin-3, ATGL, PC1/3, Syntaxin 6, and Syntaxin 12/13 was assessed by Western blotting, while NBD-ceramide fluorescence was examined by fluorescence microscopy. Metabolic stress affected Golgi stress-associated proteins and increased SMPD1 and SMPD2 expression. Increased NBD-ceramide fluorescence was consistent with changes in ceramide handling. Perilipin-3 increased without a corresponding change in ATGL, suggesting a shift toward lipid sequestration. High glucose alone largely preserved metabolic activity, whereas palmitate and combined glucose-palmitate exposure reduced both metabolic activity and PC1/3 expression. Syntaxin 6 and Syntaxin 12/13 remained unchanged. CONCLUSIONS: Metabolic stress was associated with concurrent changes in Golgi stress-associated proteins, sphingolipid metabolism, lipid droplet regulation, and PC1/3 expression in INS-1E β-cells. These findings demonstrate coordinated molecular alterations involving Golgi stress-associated proteins, sphingolipid metabolism, lipid droplet regulation, and PC1/3 expression during metabolic stress. Functional and lipidomic studies are now needed to determine how these molecular changes contribute to β-cell dysfunction.

Molecular biology reports 2026 Oct 10 PubMed
16 Adropin signaling pathways in metabolic and non-metabolic disorders. Valizadeh A et al. 10.1007/s11033-026-12896-3
View abstract

Adropin is a secreted 76-amino-acid peptide encoded by the energy homeostasis-associated gene ENHO. First identified in 2008 as a nutrient-responsive signal linking macronutrient intake with energy balance and lipid metabolism, it is now recognized as a pleiotropic hormone with actions extending well beyond classical metabolic tissues. Circulating adropin is typically reduced in obesity, type 2 diabetes, metabolic dysfunction-associated steatotic liver disease, atherosclerosis, heart failure, cognitive aging, and several fibrotic and reproductive disorders. However, diabetic kidney disease and some acute stress states show the opposite pattern. Two cell-surface partners, the orphan G-protein-coupled receptor GPR19 and the GPI-anchored neuronal protein NB-3/CNTN6, initiate overlapping but tissue-specific cascades: AMPK/ACC, PI3K/Akt/eNOS, GPR19/MAPK/PDK4, Notch1/Hes1, and TGF-β/GLI1. Through these pathways, adropin improves insulin action and mitochondrial fuel selection, increases endothelial nitric oxide bioavailability, restrains vascular remodeling, preserves blood-brain barrier integrity, and represses fibroblast activation. This review (i) separates metabolic from non-metabolic disease evidence, (ii) introduces an explicit evidence map distinguishing direct evidence, indirect evidence, and genuine controversy for every receptor and pathway, (iii) adds dedicated coverage of central feeding control, calcium-handling dysregulation in coronary disease, TGF-β/GLI1 signaling, biomarker interpretation, and translational pharmacology, and (iv) argues that progress now depends on receptor definition, assay harmonization, and delivery chemistry rather than on further disease associations. Remaining barriers include peptide instability, blood-brain-barrier delivery, non-standardized immunoassays, incomplete receptor pharmacology, and a narrow or bidirectional therapeutic window in kidney injury and tumor immunity.

Molecular biology reports 2026 Oct 10 PubMed
17 Apolipoprotein CIII as a therapeutic target in obesity-associated metabolic dysfunction. Valladolid-Acebes I et al. 10.1016/j.jbior.2026.101183
View abstract

Apolipoprotein CIII (apoCIII) is a major regulator of lipid metabolism and increased levels are related to higher risk of cardiovascular disease. Increasing evidence, however, suggests that apoCIII may also play an important role in obesity-associated metabolic dysfunction and type 2 diabetes (T2D). ApoCIII inhibits lipoprotein lipase and hepatic lipases and impairs the hepatic clearance of triglyceride-rich lipoproteins, thereby promoting hypertriglyceridemia. In addition, apoCIII has been implicated in inflammatory processes that may contribute to metabolic and vascular disease. Importantly, insulin and glucose regulate apoCIII expression, providing a mechanistic link between apoCIII and the metabolic disturbances associated with obesity and diabetes. In this review, we summarize current evidence concerning the relationship between apoCIII and obesity-associated metabolic dysfunction. Diet-induced and genetic models of obesity exhibit elevated circulating apoCIII levels as well as increased apoCIII expression in pancreatic islets. Elevated apoCIII is associated with impaired lipid metabolism, adipose tissue dysfunction, inflammation, insulin resistance, and disturbed glucose homeostasis. Conversely, pharmacological reduction of apoCIII using antisense oligonucleotides improves the metabolic dysfunctions. These effects appear to involve mechanisms extending beyond triglyceride lowering, including enhanced lipoprotein clearance, increased hepatic fatty-acid oxidation and ketogenesis, and increased thermogenic activity in adipose tissue. Preliminary clinical evidence suggests that apoCIII reduction may also improve lipid and glucose metabolism and insulin sensitivity in individuals with obesity, T2D, and hypertriglyceridemia. ApoCIII therefore represents a potential therapeutic target in obesity-associated metabolic disease. Further clinical studies are needed to establish the efficacy, safety, and long-term metabolic effects of targeted apoCIII lowering in obesity and diabetes in humans.

Advances in biological regulation 2026 Oct 8 PubMed
18 The Impact of a Low Glycemic Load Breakfast on Diurnal Glucose Profiles in Women with Gestational Diabetes Mellitus: The GLIDING Randomized Crossover Trial. Burk J et al. 10.1016/j.ajcnut.2026.101578
View abstract

BACKGROUND: Medical nutrition therapy is first-line treatment in gestational diabetes (GDM) management, yet evidence-based approaches remain lacking. In women with GDM, increased morning insulin resistance often results in postprandial (breakfast) hyperglycemia, potentially leading to increased 24-h glycemic variability (GV). OBJECTIVE: In a short-term randomized crossover control trial, we compared the effects of a low glycemic load (GL) breakfast (LGL-B) to a high GL breakfast (HGL-B) on 1-h postprandial breakfast glucose (PPG) and 24-h GV (coefficient of variation [%CV]) in women with GDM. METHODS: Women were provided an LGL-B (245 kcal; 10.9g carbohydrate) and HGL-B (247 kcal; 43.4g carbohydrate) in random order for 7 days, separated by a 7-day washout. Fasting blood was drawn on Days 1, 8, 15 and 22 (pre/post 7-day interventions) and blinded continuous glucose monitoring was undertaken. Breakfast 1-h PPG and %CV were analyzed using mixed effect models to compare between intervention effects with Bonferroni adjustments. RESULTS: Of 32 women with GDM randomized (median 34.2 years, BMI 28.1 kg/m, 27 weeks' gestation), 20 women completed both 7-day interventions and had ≥48-h CGM data for each breakfast intervention. Compared to an HGL-B, an LGL-B had lower 1-h PPG (HGL-B: mean 7.5 mmol/L [95% CI 7.2, 7.8]; 134 mg/dL [129, 140]; LGL-B: 5.0 mmol/L [4.7, 5.2]; 89 mg/dL [84, 94], p<0.001) and 24-h %CV (HGL-B: 20% [18, 21]; LGL-B: 17% [15, 18], p<0.001). There were no detectable differences between interventions for fasting lipids, ketones, satiety scores and physical activity. CONCLUSIONS: In women with GDM, an LGL-B was associated with lower breakfast PPG and 24-h %CV. Targeting breakfast may be a simple dietary strategy to improve glycemia and reduce morning bolus insulin requirements. TRIAL REGISTRATION: Australian and New Zealand Clinical Trials Registry (Identifier: ACTRN12623000425695) URL: https://anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12623000425695.

The American journal of clinical nutrition 2026 Oct 10 PubMed
19 Association of ophthalmic disease and physical activity in All of Us Research Program. Chatra N et al. 10.1016/j.jshs.2026.101182
View abstract

BACKGROUND: The association between physical activity (PA) and ophthalmic disease remains uncertain, as most studies relied on self-report. This study aimed to evaluate the associations between long-term, objectively measured PA by wearable devices (Fitbit) and the incidence and prevalence of common ophthalmic diseases in the All of Us Research Program. METHODS: We conducted cross-sectional and longitudinal analyses of 14,757 adults with electronic health record (EHR) and Fitbit data. Participants had at least 6 months of valid Fitbit wear (≥10 h/day and ≥100 steps/day). The cohort had a mean age of 55.0 ± 15.7 years (mean ± SD); 70.4% were female, and 79.1% were White. Mean daily step counts and minutes of moderate-to-vigorous physical activity (MVPA) were evaluated in relation to age-related macular degeneration (AMD), diabetic retinopathy (DR), primary open-angle glaucoma (POAG), and senile cataract identified using International Classification of Diseases codes. Logistic regression estimated odds ratios (ORs) for prevalent disease, and Cox proportional hazards models estimated hazard ratios (HRs) for incident disease. Models were adjusted for age, sex, race, and body mass index. DR analyses were also restricted to participants with diabetes mellitus. RESULTS: In cross-sectional analyses, higher PA was significantly associated with lower odds of DR among participants with DM (steps per 1000: OR = 0.91, 95% confident interval (95%CI): 0.86-0.95; p < 0.001; MVPA per 10 min: OR = 0.87, 95%CI: 0.82-0.93; p < 0.001). No significant cross-sectional associations were observed between PA and AMD, POAG, or senile cataract. In longitudinal analyses, higher PA predicted a lower risk of incident DR among participants with DM (steps: HR = 0.93, 95%CI: 0.87-0.99; p = 0.022; MVPA: HR = 0.86, 95%CI: 0.79-0.93; p < 0.001). No significant longitudinal associations were found between PA and AMD, POAG, or senile cataract. CONCLUSION: Our findings suggest a strong inverse association between sustained PA and incident DR and underscore the value of long-term wearable data for ophthalmic research.

Journal of sport and health science 2026 Oct 10 PubMed
20 Vitamin D Deficiency Associated Dyslipidemia in Type 2 Diabetes and Changes Following Vitamin D(2) Supplementation. Wang X et al. 10.1016/j.jsbmb.2026.107135
View abstract

Vitamin D deficiency (VDD) is common in type 2 diabetes mellitus (T2DM) and has been linked to dyslipidemia, but the specific lipids associated with low vitamin D status are not well defined. To address this, we sought to characterize lipidomic alterations associated with VDD in T2DM and describe the changes following vitamin D₂ (VD2) supplementation. Specifically, untargeted serum lipidomics with anthropometric and clinical measurements were performed in 219 adults with T2DM, classified as VDD (25(OH)D < 20ng/mL; n = 138) or non-VDD (25(OH)D ≥ 20ng/mL; n = 81). A subset of VDD participants (n = 20) completed a 3-month VD2 supplementation trial. Lipids were profiled by UHPLC-HRMS and analyzed in relation to metabolic and anthropometric measures. Our analysis identified 112 lipid species differentially expressed in VDD, characterized by reduced ether-linked phosphatidylcholines (EtherPCs) and elevated ceramide 16:0. EtherPCs showed negative correlation with HbA1c, BMI, as well as body fat, and positive associations with muscle mass and bone mineral content, whereas ceramides inversely associated with these metabolic indices. Following 3-month VD2 supplementation, increases in circulating 25(OH)D and reductions in HbA1c were observed, accompanied by changes on the targeted lipidome, including elevated EtherPCs and reduced ceramide profiles (Cer 20:0, Cer 22:0, Cer 16:0/24:0). In conclusion, VDD in T2DM is associated with a distinct lipidomic profile marked by EtherPCs depletion and ceramide accumulation. The observed lipidomic changes following VD2 supplementation suggest the presence of a VD2-responsive lipid signature, which may have potential implications for metabolic risk management in T2DM.

The Journal of steroid biochemistry and molecular biology 2026 Oct 10 PubMed
21 Successful bilateral lung transplantation in a patient with severe pulmonary blastomycosis. Bartolomé G et al. 10.1016/j.ajt.2026.10.008
View abstract

Severe pulmonary blastomycosis may progress to acute respiratory distress syndrome (ARDS) necessitating prolonged extracorporeal support, and ultimately lead to irreversible pulmonary injury. Whether these patients should proceed to lung transplantation remains controversial. We report a 38-year-old man with type 2 diabetes mellitus who developed fulminant pulmonary blastomycosis following environmental exposure in Ontario, Canada. Despite prolonged treatment with liposomal amphotericin B and azole therapy, his course was complicated by respiratory failure requiring mechanical ventilation, and prolonged venovenous extracorporeal membrane oxygenation (VV-ECMO), with concomitant recurrent ventilator-associated bacterial pneumonias and treatment-related nephrotoxicity. Although microbiologic markers gradually improved, including declining urinary Blastomyces antigen levels and negative respiratory fungal cultures, lung function recovery failed to occur. Ongoing uncertainty persisted regarding uncontrolled infection versus irreversible pulmonary injury. The patient ultimately underwent successful bilateral lung transplantation while receiving antifungal therapy. Post-transplant recovery progressed slowly but smoothly, with liberation from ECMO and no evidence of recurrent fungal disease. This case suggests that concern for invasive fungal infection persistence should not automatically preclude lung transplantation as a means of survival for irreversible lung injury when assessment supports favorable microbiologic control.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 2026 Oct 10 PubMed
22 Dietary Patterns and Their Association with Postpartum Glucose Metabolism Disorders after Gestational Diabetes Mellitus. Ruiz-Martínez ML et al. 10.1016/j.arcmed.2026.103522
View abstract

AIM: To identify dietary patterns and evaluate their association with postpartum glucose metabolism disorders after gestational diabetes mellitus (GDM). METHODS: A nested case-control study was conducted in women aged 18-40 with GDM (n = 233) who participated in an educational intervention program. Clinical, biochemical, and anthropometrical parameters were evaluated at the end of pregnancy and three months postpartum. An oral glucose tolerance test (OGTT) with 75 g glucose was performed three months after giving birth. Women were classified as follows: i) Those with glucose metabolism disorders (n = 100), fasting plasma glucose (FPG) ≥100 mg/dL and/or ≥140 mg/dL at 2 h; ii) Those with normal glycemia (n = 133), FPG <100 mg/dL and <140 mg/dL at 2 h. For this study, we defined postpartum glucose metabolism disorders as having impaired fasting glucose and/or impaired glucose tolerance, or type 2 diabetes. Dietary patterns were analyzed using factor analysis and multivariate logistic regression to identify associations with postpartum glucose metabolism disorders, after adjusting for confounders. RESULTS: Three dietary patterns were identified. The highest compared to the lowest adherence to a healthy postpartum dietary pattern was associated with lower odds (OR 0.445; 95% CI 0.209-0.951; p = 0.037) of postpartum glucose metabolism disorders; no association was found for the Western dietary pattern or the Sweets and Dairy-Rich in Fat and Sugar dietary pattern. CONCLUSION: In women with previous GDM, the highest compared to the lowest adherence to the Healthy postpartum dietary pattern was associated with lower odds of postpartum glucose metabolism disorders.

Archives of medical research 2026 Oct 9 PubMed
23 PRAP1 aggravates palmitate-induced insulin resistance in skeletal muscle cells through a CD36-dependent mechanism. Lee JS et al. 10.1016/j.bbrc.2026.154722
View abstract

Proline-rich acidic protein 1 (PRAP1) is involved in intestinal lipid handling, but its role in skeletal muscle insulin resistance is unknown. We examined circulating PRAP1 in normal diet- and high-fat diet-fed mice and evaluated PRAP1 expression and secretion in palmitate-treated intestinal epithelial cells, together with its functional effects in differentiated C2C12 myotubes. PRAP1 expression and secretion were assessed following palmitate exposure, while C2C12 myotubes were treated with recombinant PRAP1 and palmitate followed by insulin stimulation. CD36 expression, fatty acid uptake, intracellular ceramide, and insulin signaling were evaluated, and the involvement of CD36 was examined pharmacologically. Serum PRAP1 levels were increased in high-fat diet-fed mice, and palmitate increased PRAP1 expression and secretion from intestinal epithelial cells. PRAP1 alone minimally affected insulin signaling but markedly exacerbated the palmitate-induced impairment of IRS-1/Akt signaling in C2C12 myotubes. This effect was accompanied by increased CD36 expression, fatty acid uptake, and ceramide accumulation. CD36 inhibition reduced fatty acid uptake and ceramide accumulation and restored insulin-stimulated IRS-1/Akt phosphorylation. These findings identify PRAP1 as a conditional amplifier of lipotoxic insulin resistance and suggest that PRAP1 may contribute to obesity-associated skeletal muscle insulin resistance through CD36-dependent increases in fatty acid uptake and ceramide accumulation.

Biochemical and biophysical research communications 2026 Oct 9 PubMed
24 The transition from pre- to early pregnancy for women with type 2 diabetes - a qualitative study. Lorenzen LE et al. 10.1016/j.midw.2026.105011
View abstract

BACKGROUND: Pregnant women with type 2 diabetes and their offspring face an increased risk of obstetric complications, necessitating major changes in diabetes self-care during pregnancy. These changes include the initiation of insulin therapy, frequent blood glucose monitoring, carbohydrate counting and regular hospital visits. For many women, this transition is challenging and emotionally demanding. To improve care and support during this vulnerable period, gaining a deeper understanding of these women's experiences is essential. AIM: To explore how women with type 2 diabetes experience the transition from pre-pregnancy to early pregnancy. METHODS: Semi-structured interviews were conducted with 13 pregnant women with type 2 diabetes in early pregnancy (gestational week 10-16) who received care in the Region of Southern Denmark between March and November 2023. The study used a phenomenological-hermeneutic approach and interpretative phenomenological analysis. FINDINGS: Four main themes identified: 1) Being prepared for pregnancy and diabetes 2) Experiencing diabetes in a new way 3) A new everyday life 4) Adapting to life changes. The transition from pre-pregnancy to early pregnancy involved significant changes related to diabetes self-care, everyday life and self-perception. How the women experienced these changes was shaped by whether they felt prepared for pregnancy with type 2 diabetes. CONCLUSION: The transition to early pregnancy involves complex emotional and practical shifts in women with type 2 diabetes. These shifts involve seeing themselves, their lives and their disease in a new context and highlight the need for personalized support during this vulnerable period.

Midwifery 2026 Oct 8 PubMed
25 Efficacy of Topical Emollients on Skin Biophysical Properties and Inflammatory Markers in Stasis Eczema. Goon JA et al. 10.1159/spp/aetag006
View abstract

INTRODUCTION: Stasis eczema is a chronic inflammatory skin condition commonly associated with chronic venous insufficiency and represents a significant clinical burden. Emollients are widely used to improve skin hydration and barrier function; however, their effects on inflammation and skin remodeling in stasis eczema remain unclear. This study aimed to evaluate the impact of a topical emollient on skin barrier integrity and systemic inflammatory markers in affected patients. METHODS: Fifty patients with stasis eczema were randomized to receive either a topical emollient or placebo for six weeks. Skin parameters, including melanin content, hydration, and transepidermal water loss (TEWL), were assessed using Tewameter. Plasma levels of pro-inflammatory cytokines (IL-6, IL-1β, TNF-α), anti-inflammatory cytokine IL-10, and matrix metalloproteinases (MMP-1, MMP-2, MMP-3, and MMP-9) were measured using enzyme-linked immunosorbent assay (ELISA) at baseline and after treatment. RESULTS: Baseline clinical assessment demonstrated a high prevalence of comorbidities, particularly hypertension, chronic venous insufficiency, diabetes mellitus, and dyslipidemia. No statistically significant changes were observed in skin barrier parameters or circulating cytokine levels following six weeks of treatment. MMP-1 and MMP-2 concentrations remained stable in both groups. However, post-treatment MMP-3 levels were significantly higher in the emollient group than in the placebo group, while MMP-9 demonstrated a significant within-group change in the placebo group only. CONCLUSION: Short-term use of a topical emollient may help maintain skin barrier function and systemic inflammatory status but does not appear to produce clinically meaningful improvements in most skin barriers or inflammatory parameters, despite isolated significant changes observed in specific MMP biomarkers in patients with chronic stasis eczema. These findings highlight the complexity of disease management in this population and suggest that longer treatment durations, larger sample sizes, consideration and statistical adjustment for baseline comorbidities are warranted in future studies.

Skin pharmacology and physiology 2026 Oct 10 PubMed
DoctiPlus Health Insights are compiled weekly from public trial registries, FDA databases, and academic publishers. All figures reflect the seven-day window ending on the report date. Data is provisional and subject to registry updates.

Primary sources

  • ClinicalTrials.gov — public registry
  • openFDA — adverse events & recalls
  • PubMed / NCBI — research papers
  • Semantic Scholar — citations & papers

About this report

  • Category: Diabetes (Type 2)
  • Week: October 5 – October 12, 2026
  • Drugs tracked: New Trials This Week, Recruiting Now, Countries
  • Generated: November 15, 2026 at 5:56 AM
© 2026 DoctiPlus Care Vol. 7 · No. 46 · November 15, 2026 — 30 —